Argenx saw the highest growth of 2.49% in patent filings in May and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Argenx‘s patent filings and grants. Buy the databook here.
Argenx has been focused on protecting inventions in European Patent Office(EPO) with six publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 22% filings and 25% grants. The European Patent Office(EPO), United States(US), World Intellectual Property Organization(WIPO), and Argentina(AR) patent Office are among the top ten patent offices where Argenx is filings its patents. Among the top granted patent authorities, Argenx has 25% of its grants in European Patent Office(EPO).
Regeneron Pharmaceuticals could be the strongest competitor for Argenx
Patents related to rare diseases lead Argenx's portfolio
Argenx has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Preleukemia related patents lead Argenx portfolio followed by leukemia, and advanced malignancy
Argenx has highest number of patents in preleukemia followed by leukemia, advanced malignancy, nebulizers, and cystic fibrosis. For preleukemia, nearly 11% of patents were filed and 38% of patents were granted in Q2 2024.
For comprehensive analysis of Argenx's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.